333 related articles for article (PubMed ID: 35014121)
1. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
Shanmukhaiah C; Jijina F; Kannan S; Pai NG; Kulkarni B; Khuba SV; Shaikh M; Joshi A; Phatale R; Apte S
Haemophilia; 2022 Mar; 28(2):286-291. PubMed ID: 35014121
[TBL] [Abstract][Full Text] [Related]
2. Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease.
Yaoi H; Shida Y; Ogiwara K; Kitazawa T; Shima M; Nogami K
Haemophilia; 2022 Sep; 28(5):694-701. PubMed ID: 35478475
[TBL] [Abstract][Full Text] [Related]
3. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Haemophilia; 2021 Mar; 27(2):e194-e203. PubMed ID: 33555083
[TBL] [Abstract][Full Text] [Related]
4. Navigating the challenges: a case report on managing a complicated postpartum course in type 3 von Willebrand disease with alloantibodies.
van der Zwet K; van Galen KPM; Evers ACC; Fischer K; Schutgens REG; van Vulpen LFD
Res Pract Thromb Haemost; 2024 Mar; 8(3):102399. PubMed ID: 38689620
[TBL] [Abstract][Full Text] [Related]
5. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
[TBL] [Abstract][Full Text] [Related]
6. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.
Thomas VM; Abou-Ismail MY; Lim MY
Haemophilia; 2022 Jan; 28(1):4-17. PubMed ID: 34820989
[TBL] [Abstract][Full Text] [Related]
7. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
8. Analysis of current perioperative management with Haemate
Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
[TBL] [Abstract][Full Text] [Related]
9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review.
Giuffrida AC; Siboni SM; Baronciani L; Poli G; Gandini G; Peyvandi F
Semin Thromb Hemost; 2024 Jun; ():. PubMed ID: 38936417
[TBL] [Abstract][Full Text] [Related]
11. Treatment of von Willebrand disease.
Rodeghiero F; Castaman G
Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
[TBL] [Abstract][Full Text] [Related]
12. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Auerswald G; Kreuz W
Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
14. The potential role of emicizumab prophylaxis in severe von Willebrand disease.
Barg AA; Avishai E; Budnik I; Brutman TB; Tamarin I; Dardik R; Bashari D; Misgav M; Lubetsky A; Lalezari S; Livnat T; Kenet G
Blood Cells Mol Dis; 2021 Mar; 87():102530. PubMed ID: 33341070
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
17. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
18. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
Bravo MI; Raventós A; Pérez A; Costa M; Willis T
J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
[TBL] [Abstract][Full Text] [Related]
19. Towards novel treatment options in von Willebrand disease.
Lenting PJ; Kizlik-Manson C; Casari C
Haemophilia; 2022 May; 28 Suppl 4():5-10. PubMed ID: 35521728
[TBL] [Abstract][Full Text] [Related]
20. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
